Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1278863A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Active Drug |
| Group 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| 1278863A | DRUG | 25mg, 50mg, 100mg |
| Placebo | DRUG | matching placebo |
Inclusion Criteria: 1. Male or female between 18 and 85 years of age inclusive, at the time of signing the informed consent. 2. A male or female is eligible to enroll and participate in this study if he/she: 1. (Part 1) has Moderate to Severe Renal Impairment (equivalent to NKF KDOQI Stage 3 or...
Top 20 of 25 competitors
1278863A is an investigational small molecule being studied for the treatment of Kidney Disease. It is currently in Phase 2 clinical development, with one completed trial that evaluated repeat doses of the compound for anemia in patients with kidney disease.
1278863A is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research on this investigational compound for kidney disease.
1278863A is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating kidney disease.
1278863A has one completed clinical trial registered as NCT01047397, titled "Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia." This Phase 2 study enrolled 107 participants with kidney disease across Australia, India, New Zealand, and Russia.
No alternative names for 1278863A have been disclosed. The compound is identified by its developmental code 1278863A and is being investigated by GSK plc for the treatment of kidney disease.